Arie Belldegrun

Arie Belldegrun, MD, is a distinguished figure in the field of urologic oncology and biotechnology. Currently serving on the Board of Directors for ByHeart, Ginkgo Bioworks, and IconOVir Bio, Belldegrun also co-chairs Breakthrough Properties and is a professor and director at the UCLA Institute of Urologic Oncology. As an influential leader, Belldegrun has held prominent positions, including Executive Chairman and Co-Founder of Allogene Therapeutics, Chairman of the Board at Kronos Bio, Inc., and Founder, Chairman, President, and CEO of Kite Pharma. With a robust academic background, including degrees from Hadassah Medical School and Harvard Medical School, as well as surgical oncology training at the National Cancer Institute/NIH, Belldegrun has made significant contributions to the fields of medicine and biotechnology.